Form 4: Pfizer CFO Denton Modifies Stock Appreciation Rights

David M. Denton, CFO of Pfizer, modifies stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years.

Summary

• David M. Denton, the Chief Financial Officer & EVP of Pfizer Inc., filed a Form 4 on September 16, 2024, regarding changes in beneficial ownership.
• The filing details the modification of stock appreciation rights (TSRUs) under a one-time offer by Pfizer.
• Denton elected to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years.
• The grant price and number of shares underlying the Modified TSRUs remain unchanged.
• Specifically, 103,320 TSRUs with a grant price of $42.3 were modified to extend the expiration date from February 23, 2028, to February 23, 2030.
• Additionally, 80,703 TSRUs with a grant price of $53.04 were modified to extend the expiration date from May 31, 2027, to May 31, 2029.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation adjustment, suggesting stability and alignment of management interests with long-term shareholder value. It's a neutral to slightly positive development.

Positives

• The modification of TSRUs provides Denton with a longer-term incentive tied to Pfizer's performance.
• The extension of the vesting period may align Denton's interests more closely with long-term shareholder value creation.

Future Outlook

The modification of the TSRUs suggests a continued commitment by Pfizer to incentivize its executives with long-term equity-based compensation.

Management Comments

• The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years.
• The grant price and number of shares underlying the Modified TSRUs remain unchanged.

Industry Context

Executive compensation packages often include stock appreciation rights or similar equity-based awards to align management's interests with those of shareholders. Extending the vesting period is a common practice to further incentivize long-term performance.

Comparison to Industry Standards

• Companies like Johnson & Johnson and Merck also utilize stock options and restricted stock units as part of their executive compensation packages.
• The specific terms of these awards, such as vesting schedules and performance metrics, vary depending on the company's compensation philosophy and industry practices.
• Extending vesting periods for equity awards is a common practice to encourage long-term value creation, similar to what Pfizer has done with Denton's TSRUs.

Stakeholder Impact

• Shareholders may view the modification of TSRUs as a positive sign, indicating that management is incentivized to focus on long-term value creation.
• Employees may see this as a reflection of Pfizer's commitment to rewarding its executives for their contributions to the company's success.

Key Dates